The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada

M. de Bruin-Weller, A. Gadkari, S. Auziere, E. L. Simpson, L. Puig, S. Barbarot, G. Girolomoni, K. Papp, A. E. Pink, G. Saba, T. Werfel, L. Eckert

Research output: Contribution to journalArticle

Abstract

Background: Cross-sectional data on patient burden in adults with atopic dermatitis (AD) from real-world clinical practice are limited. Objective: This study compared patient-reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. Methods: This study included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient-Oriented-Scoring of Atopic Dermatitis (PO-SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. Results: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. Conclusions: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD.

Original languageEnglish (US)
Pages (from-to)1026-1036
Number of pages11
JournalJournal of the European Academy of Dermatology and Venereology
Volume34
Issue number5
DOIs
StatePublished - May 1 2020

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada'. Together they form a unique fingerprint.

  • Cite this

    de Bruin-Weller, M., Gadkari, A., Auziere, S., Simpson, E. L., Puig, L., Barbarot, S., Girolomoni, G., Papp, K., Pink, A. E., Saba, G., Werfel, T., & Eckert, L. (2020). The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. Journal of the European Academy of Dermatology and Venereology, 34(5), 1026-1036. https://doi.org/10.1111/jdv.16003